Unlocking gene control mechanisms to develop small molecule therapies


Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes.


Year Invested: 2016
Location: Cambridge, MA
Visit: www.fulcrumtx.com

Recent News

February 20, 2019
Fulcrum Therapeutics Appoints Christopher Moxham, Ph.D. as SVP, Discovery

January 4, 2019
Fulcrum Therapeutics to Present at Biotech Showcase 2019

January 3, 2019
Fulcrum Therapeutics Appoints Biotech Executive Bryan Stuart as Chief Operating Officer

Read More News

Associated Team Members

Mark Levin
Partner

Philip Reilly, M.D., J.D.
Venture Partner

Walter Kowtoniuk, Ph.D.
Principal